{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T11:36:26Z","timestamp":1792236986097,"version":"4.4.0"},"reference-count":41,"publisher":"Informa UK Limited","issue":"11-12","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1080\/17425255.2024.2401603","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T04:04:20Z","timestamp":1725941060000},"page":"1023-1036","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata"],"prefix":"10.1080","volume":"20","author":[{"given":"Mariela","family":"Nunez","sequence":"first","affiliation":[{"name":"Chemometrics and Molecular Modeling Laboratory, Department of Chemistry and Physics, Kean University, Union, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9411-2091","authenticated-orcid":false,"given":"Supratik","family":"Kar","sequence":"additional","affiliation":[{"name":"Chemometrics and Molecular Modeling Laboratory, Department of Chemistry and Physics, Kean University, Union, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Chemometrics and Molecular Modeling Laboratory, Department of Chemistry and Physics, Kean University, Union, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariel","family":"Ondieki","sequence":"additional","affiliation":[{"name":"Chemometrics and Molecular Modeling Laboratory, Department of Chemistry and Physics, Kean University, Union, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,9,9]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/12034754231168839"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.4103\/idoj.idoj_452_22"},{"key":"e_1_3_6_5_1","unstructured":"DrugBank. Ritlecitinib: uses interactions and mechanisms of action. DrugBank online. Available from: https:\/\/go.drugbank.com\/drugs\/DB14924#BE0003493LITFULO"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S334727"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.950450"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.oprd.9b00198"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01928-y"},{"key":"e_1_3_6_10_1","unstructured":"Pfizer Inc. European Commission approves Pfizer\u2019s LITFULO\u2122 for adolescents and adults with severe alopecia areata. Pfizer; 2023 Sep 19. Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/european-commission-approves-pfizers-litfulotm-adolescents"},{"key":"e_1_3_6_11_1","unstructured":"BioWorld. China\u2019s NMPA approves Pfizer\u2019s third-generation ALK inhibitor lorbrena in NSCLC. BioWorld; 2022 May 3. Available from: https:\/\/www.bioworld.com\/articles\/691280-chinas-nmpa-approves-pfizers-third-generation-alk-inhibitor-lorbrena-in-nsclc"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/psb.0010146"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tet.2021.132503"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crimmu.2021.02.001"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.03.050"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells10123397"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1243556"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-021-08883-0"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S309215"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medidd.2023.100161"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.5114\/ceji.2020.101264"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00791-1"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/antiox12010135"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1159\/000485080"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.10.036"},{"key":"e_1_3_6_26_1","unstructured":"Pfizer Inc. Pfizer Canada. Product monograph including patient medication information: LITFULO ritlecitinib capsules - capsule 50 mg ritlecitinib (as ritlecitinib tosylate). Oral use: selective JAK3 & TEC family kinase inhibitor. 2023 Sep 29. Available from: https:\/\/pdf.hres.ca\/dpd_pm\/00073579.PDF"},{"key":"e_1_3_6_27_1","unstructured":"Pfizer Inc. LITFULO (ritlecitinib) capsules for oral use. 2023 Jun. Available from: https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=19638#section-11.2"},{"key":"e_1_3_6_28_1","unstructured":"Ritlecitinib (LITFULO) in alopecia areata national drug monograph December 2023. Available from: https:\/\/www.va.gov\/formularyadvisor\/DOC_PDF\/MON_Ritlecitinib_LITFULO_in_Alopecia_Areata_Monograph_Dec_2023.pdf"},{"key":"e_1_3_6_29_1","unstructured":"FDA. Multi-disciplinary Review and Evaluation for NDA 215830 Litfulo(Ritlecitinib)capsule. 2023 Jun 22. Available from: https:\/\/www.fda.gov\/media\/172964\/download?attachment"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.15378"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00997-x"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17909"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2022.100156"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.12.008"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2023.06.071"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.12.029"},{"key":"e_1_3_6_37_1","unstructured":"Medscape. Litfulo (ritlecitinib) dosing indications interactions adverse effects and more. Available from: https:\/\/reference.medscape.com\/drug\/litfulo-Ritlecitinib-4000322#11"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.5281\/zenodo.10442173"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1472-8206.2003.00193.x"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.124088"},{"key":"e_1_3_6_41_1","unstructured":"Miranda-Cantellops N Tiu TK. Berg balance testing. Treasure Island (FL): StatPearls Publishing; 2024 [Updated 2023 Feb 17]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK574518\/"},{"key":"e_1_3_6_42_1","article-title":"Litfulo: dosage, side effects, uses, interactions, cost, and more","author":"Scheffel E","year":"2024","unstructured":"Scheffel E, Marshall H. Litfulo: dosage, side effects, uses, interactions, cost, and more. Med News Today. 2024 Jan 9. Available from: https:\/\/www.medicalnewstoday.com\/articles\/drugs-litfulo#interactions","journal-title":"Med News Today"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.11.005"}],"container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425255.2024.2401603","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T11:14:07Z","timestamp":1733310847000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425255.2024.2401603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,9]]},"references-count":41,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1080\/17425255.2024.2401603"],"URL":"https:\/\/doi.org\/10.1080\/17425255.2024.2401603","relation":{},"ISSN":["1742-5255","1744-7607"],"issn-type":[{"value":"1742-5255","type":"print"},{"value":"1744-7607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-07-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}